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Clinical impact of low serum free T4 
in patients with non-small cell lung 
cancer treated with nivolumab
tomoko Yamamoto funazo  , takashi nomizo, Hiroaki ozasa*, takahiro tsuji  , Yuto Yasuda  , 
Hironori Yoshida, Yuichi Sakamori, Hiroki nagai, toyohiro Hirai & Young Hak Kim
nivolumab improves the prognosis of non-small cell lung cancer (nScLc) but can cause immune-related 
adverse events (irAes). Reports have indicated longer progression-free survivals (pfSs) in patients with 
irAEs than in those without irAEs. We reported associations between programmed death ligand-1 (PD-
L1) single nucleotide polymorphisms (SNPs) and PFS after nivolumab treatment. We hypothesized that 
adverse events might be associated with the SNPs of PD-L1. We analyzed data from 111 patients with 
NSCLC treated with nivolumab. The response rate was 14%, and the median PFS was 68 days. We found 
patients with the adverse event of low free tetraiodothyronine (fT4) had significantly longer PFSs than 
those without low fT4 (not reached vs 67 days; hazard ratio [HR], 0.297; P = 0.010). Moreover, median 
overall survival was longer in patients with low fT4 than those without low fT4 (not reached vs 556 
days, HR, 0.139; P = 0.020). Patients with the T allele of rs1411262 (P = 0.0073) and with the A allele 
of rs822339 (P = 0.0204) developed low fT4. Patients with the T/T genotype had longer PFSs than with 
those with the C/T and C/C genotypes of rs1411262 (165 vs. 67 days, HR, 1.65; P = 0.040), and those 
with the A/A genotype had longer PFSs than those with the A/G and G/G genotypes of rs822339 (182 vs. 
67 days, HR, 1.76; P = 0.025). In the patients with advanced NSCLC, low fT4 after nivolumab treatment 
was associated with significantly longer PFSs. The SNPs of PD-L1 may be associated with the adverse 
events of nivolumab.
Nivolumab is one of the immune-checkpoint inhibitors (ICIs) that inhibits the programmed death 1 (PD-1) and 
the programmed death ligand 1 (PD-L1) pathways and releases effector T cells as a defense against tumor cells. 
Nivolumab dramatically improved the prognosis of patients with non-small cell lung cancer (NSCLC) with clin-
ical trials showing longer overall survivals (OS) in the nivolumab-treated than in the docetaxel-treated patients 
with advanced NSCLC1,2. In addition, some patients had responses lasting more than 2 years3; although this 
response rate can be as low as 20%. Biomarkers including PD-L1 expression in the tumor cells4, the presence of 
tumor-infiltrating lymphocytes at the invasive tumor margin5, and the nonsynonymous mutation burden fre-
quency in the tumor cells6 have been shown to predict the effect of nivolumab. Although the PD-L1 tumor cell 
expression has been studied as a biomarker in many clinical trials, its prediction accuracy is limited4,7
Nivolumab treatment also results in a unique side-effect profile caused by the action of effector T cells against 
self-antigens, described as immune-related adverse events (irAEs), and includes rashes, colitis, diarrhea, thyroid-
itis, hypophysitis, hepatitis, pancreatitis, iridocyclitis, lymphadenopathy, neuropathies, and nephritis8,9. Previous 
reports have suggested that patients with ICI-induced irAEs have longer PFS and OS than those without irAEs10–
12. The irAEs could be the product of the responses to immune system activation by ICIs.
We have reported an association between single nucleotide polymorphisms (SNPs) of PD-L1 and the response 
to nivolumab13. A similar report indicated an association between SNPs and the response to other ICIs14. 
Moreover, other studies have also indicated an association between the SNPs of PD-1 and PD-L1 and autoim-
mune diseases such as systemic lupus erythematosus15, type 1 diabetes16, and Addison’s disease, and Graves’ dis-
ease17,18. According to these reports, the SNPs of PD-L1 may be associated with the functioning of the PD-1 and 
PD-L1 pathway. However, the association between SNPs and the adverse events of ICIs remains unclear.
We hypothesized that the adverse events of nivolumab in patients with NSCLC might be associated with the 
treatment response and with PD-1/PD-L1 SNPs. We retrospectively analyzed data from patients with advanced 
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NSCLC treated with nivolumab to assess the association between adverse events and response, and the associa-
tion between adverse events and PD-1/PD-L1 SNPs.
Results
patients’ characteristics. Table 1 lists patients’ characteristics. The median age was 68 years with a wide 
range from 33 to 85 years, and 73 patients (66%) were men. Most patients (91%) had an ECOG PS of 0 or 1. 
Almost three-quarters of patients were diagnosed as having adenocarcinoma and one-fifth of patients as having 
squamous-cell carcinoma. Forty-eight patients (43%) received nivolumab as the second-line treatment, and 63 
(57%) received it as the third-line or later treatment.
clinical outcomes. Among the 111 patients, none achieved a complete response, 16 (14%) had a partial 
response (PR), 42 (38%) had stable disease (SD), and 53 (48%) had PD. The median PFS in all patients was 68 days 
(95% confidence interval [CI], 58–101 days) and was similar to that reported in a large clinical trials of nivolumab 
in patients with NSCLC1,2.
Adverse events. From 111 patients, 108 patients with follow-up blood exam were analyzed for adverse 
events. Table 2 lists the adverse events that occurred during nivolumab treatment in the participants. The most 
frequent adverse event was malaise, but grade 3 treatment-related adverse events included gastritis and headache. 
We found no grade 4 or 5 adverse events. The profile and frequency of adverse events in this study were similar to 
those reported for clinical trials of nivolumab in patients with NSCLC19,20.
Association between pfS and adverse events. The associations between PFS and each adverse event 
were analyzed for 108 patients. The median PFS was significantly longer in patients with low free tetraiodothy-
ronine (fT4) level than in those without low fT4 (not reached vs. 67 days; hazard ratio [HR]: 0.297; P = 0.010; 
Fig. 1A), and the median OS was longer in patients with low fT4 level than in those without low fT4 (not reached 
vs. 556 days; HR: 0.139; P = 0.020; Fig. 1B). We defined low fT4 levels as those below the facility standard. We 
found no significant associations between low fT4 and other clinical variables including age, gender, smoking sta-
tus, ECOG PS, number of chemotherapy cycles, histological findings, and EGFR mutation status (Supplementary 





Age Median (range) 68 (33–85)
Smoking status Never/ever 33/78
Numbers of line 2nd/≧3rd 48/63














Table 1. Patients’ characteristics.
grade 1 grade 2 grade 3 grade 4 Incidence
Malaise 19 2 0 0 20%
Liver dysfunction 21 0 0 0 19%
Thyroid dysfunction 14 6 0 0 18%
Anorexia 11 4 0 0 14%
Pneumonitis 8 1 0 0 10%
Rash 9 0 0 0 8%
Fever 4 0 0 0 4%
Oral ulcer 1 0 0 0 1%
Gastritis 0 0 1 0 1%
Headache 0 0 1 0 1%
Hypophysitis 0 1 0 0 1%
Infusion reaction 0 1 0 0 1%
Table 2. List of adverse events. Adverse events that occurred during nivolumab treatment in the participants.
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Association between Snps and Adverse events. We evaluated the prevalences of PD-1/PD-L1 SNPs 
and compared them between patients with and without individual adverse events. We found a significant associ-
ation between a low fT4 and the SNPs of PD-L1 (Table 3). The patients with the T allele of rs1411262 and the A 
allele of rs822339 were more likely to present low fT4 than patients with the C allele of rs1411262 or the G allele of 
rs82239. We found no significant associations between other adverse events and SNPs (Supplementary Table S2). 
In this study, rs1411262 and rs822339 were in linkage disequilibrium relationship (Supplementary Fig. S2).
Association of Snps and pfS. We examined the possible associations between PFS and PD-1/PD-L1 
SNPs. The T/T genotype of rs1411262 was associated with longer PFS than the C/T and C/C genotypes of 
rs1411262 (165 vs.67 days, respectively; HR, 1.65; P = 0.040; Fig. 2A) and the A/A genotype of rs822339 was also 
significantly associated with longer PFS than the A/G and G/G genotypes of rs822339 (182 vs.67 days, respec-
tively; HR, 1.76; P = 0.025; Fig. 2B).
Patients with low fT4. Supplementary Fig. S3 and Supplementary Table S3 show the characteristics of 
patients with low fT4. The median duration of time from the administration of nivolumab to the onset of thyroid 
dysfunction was 48 days. Three patients had PR, 6 patients had SD, but none had PD. Five patients discontinued 
the administration of nivolumab due to adverse events. Of the 9 patients, 5 patients have maintained tumor 
shrinkage until the publication of this paper, 2 had relapsed and 2 switched chemotherapies before disease pro-
gression at the discretion of their physicians.
Discussion
Here, we showed that patients with low fT4 had longer PFS than those without low fT4. We found associations 
between the occurrence of low fT4 and SNPs of PD-L1; rs1411262 and 822339. Patients with the T/T genotype 
of rs1411262 and the A/A genotype of rs822339 were susceptible to low T4 and had longer PFSs. This is the first 
report showing an association between SNPs of PD-L1 and the occurrence of adverse events.
We focused on the low fT4 level adverse event. The definitions of thyroid dysfunction in the literature do not 
include the criteria for thyroid dysfunction caused by ICIs. In general medical settings, thyroid dysfunction is 
often diagnosed based on a high TSH level, low fT4 level, and low free triiodothyronine (fT3) level. In the pres-
ent study, 7 patients had a TSH level ≥10 mIU/l among the 9 cases that showed low fT4 levels (Supplementary 
Table S3). High TSH levels are commonly attributed to low fT4 level feedback. The influence of nivolumab on 
this feedback is unclear. In addition, an elevated TSH level may not be confirmed based on the timing of blood 
examination. Reduction of fT3 level can occur in low T3 syndrome, a nonthyroidal illness associated with critical 
illness, including cancer21,22. We believe that fT4 level is an index that can be used for the evaluation of thyroid 
dysfunction as an adverse event of nivolumab.
Figure 1. PFS after the administration of nivolumab. The Kaplan–Meier curves for progression-free survival 
(A) and overall survival (B) are presented. The red line represents the presence of low fT4 level, and the blue line 
represents the absence of low fT4. N.R. denotes not reached.
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The thyroid dysfunction caused by nivolumab has been considered due to a direct attack by effector T cells 
against tumor-associated self-antigens19. The hypothesis on effector T cells attacking tumor as well as thyroid 
cells could explain why patients developing thyroid dysfunction tend to have a more therapeutic response to ICI 
treatment. Tanaka et al. found that one of three patients who developed thyroid dysfunction achieved complete 
remission after nivolumab treatment23. This finding was similar to our results showing that patients with low fT4 
had PR or SD. Moreover, of our nine patients who developed low fT4; two have maintained tumor shrinkage even 
after treatment interruption because of adverse events (Supplementary Fig. S3).
Although no reports have ascribed a role to PD-L1 in the onset of thyroid dysfunction including Grave’s dis-
ease and Hashimoto’s thyroiditis, PD-L1 deficiency has been associated with the onset and exacerbation of var-
ious autoimmune diseases, including type 1 diabetes24,25, rheumatoid arthritis26,27, and ankylosing spondylitis28. 
SNPs of PD-L1 have also been associated with autoimmune diseases: Mitchell et al. showed that the frequencies 
of the C allele of rs1411262 and the G allele of rs822339 were higher in patients with Addison’s disease and Graves’ 
disease than in controls18. Yang et al. reported that the C allele of rs822336 was more frequent in patients having 
ankylosing spondylitis than in controls29, and Pizarro et al. reported that the G allele of rs4143815 and the G allele 
of rs2297137 were higher in patients with type 1 diabetes than in healthy controls16. Interestingly, Shi et al. showed 
that the G/G genotype of rs4143815 was associated with lower PD-L1 expression on hepatic dendritic cells after 
IFN-γ stimulation30. These reports indicate that SNPs of PD-L1 and expression of PD-L1 may be related. The C 
allele of rs1411262 and the G allele of rs822339 are in linkage disequilibrium with the C allele of rs822336, the G 




































































AA + AG 6 71
0.714
GG 3 28
Table 3. Association between PD-1/PD-L1 SNPs and adverse events. Frequency of alleles and distribution of 
genotypes of PD-L1/ PD-1 SNPs in patients with low free T4 (n = 9) and those without low free T4 (n = 99). 
P-values are as shown in the table, and significant results are indicated in bold.
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Therefore, rs1411262 and rs822339 may also be involved in the protein expression of PD-L1 and may affect 
PD-L1 function. In this study, we evaluated seven SNPs with a relatively even distribution of allele frequencies in 
Japanese patients and reported the association with autoimmune diseases. We speculate that patients with the T 
allele of rs1411262 and the A allele of rs822339 have a low frequency of fT4 during nivolumab treatment due to 
activated immune cells that may attack the thyroid gland.
Our study had some limitations. First, it was a retrospective cohort study with a small sample size. The median 
follow-up period was about 12 months, and the OS was immature. Long-term adverse events might not have 
been fully evaluated. Large-sized studies may confirm the relevance of PD-L1 SNPs to other clinically important 
adverse events, including pneumonitis. We are planning future studies to evaluate the relevance of the adverse 
events of nivolumab and PD-1/PD-L1 SNPs (UMIN000033839). Second, PD-L1 expression has not been com-
pletely analyzed. Of the nine patients who presented with low fT4 level, one tested negative for PD-L1 (tumor pro-
portion score <1%), and the PD-L1 status of the other patients was not assessed (Supplementary Table S3). PD-L1 
expression was evaluated only in 49 (45%) patients (Supplementary Fig. S4). Thus, the relationship between TPS 
and adverse events must be assessed in future studies. Last, we selected seven PD-1/PD-L1 polymorphisms that 
were considered functional based on previous reports; however, other more efficiently predictable SNPs may exist.
In conclusion, we found that PFS is longer in patients with low fT4 than in those without low fT4 following 
treatment with nivolumab for advanced NSCLC. The T allele of rs1411262 and A allele of rs822339 were signifi-
cantly associated with low fT4 and the T/T genotype of rs1411262 and A/A genotype of rs822339 were associated 
with longer PFS. SNPs of PD-L1 may lead to the activation of the PD-1 and PD-L1 pathways that attack both 
tumor tissue and normal tissue. This is the first report to show an association between adverse events and SNPs of 
PD-L1 in patients with NSCLC treated with nivolumab.
Patients and Methods
patients. Between January 2016 and December 2017, a total of 144 consecutive patients were diagnosed with 
non-small cell lung cancer and were treated with nivolumab at the Kyoto University Hospital. Of these patients, 
111 patients were analyzed for association between PFS and PD-1/PD-L1 SNPs. We excluded patients who 
declined informed consents, patients with multiple cancer histories, patients without radiographically measura-
ble lesions, patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 3, and patients 
diagnosed with disease progression within 15 days from the first dose (Fig. 3). From these patients, 108 patients 
Figure 2. PFS after nivolumab administration shown by a Kaplan–Meier curve. The red line represents the C/C 
and C/T genotypes of rs1411262, and the blue line represents the T/T genotype of rs1411262 (A). The red line 
represents the G/G and A/G genotypes of s822339, and the blue line represents the A/A genotype of rs822339 (B).
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with follow-up blood exam were analyzed for adverse events. We collected 10-mL peripheral blood samples from 
each patient to examine genotypes. We followed the guidelines in the Declaration of Helsinki to conduct our 
study. The Review Board of the Kyoto University Hospital approved the study’s protocol (certification number: 
G0788). All participants provided written informed consents.
Genotyping and SNP selection. Genomic DNA was extracted from peripheral blood leukocytes using 
Gene Prep Star NA-480 (Kurabo, Osaka, Japan). Genotyping was performed using the TaqMan® genotyping 
assay (Applied Biosystems, Foster City, CA. USA) and analyzed using the Applied Biosystems 7300 Real-Time 
polymerase chain reaction (PCR) System (Applied Biosystems). The PCR solution contained a 1-µL DNA sample, 
12.5 µL of 2X TaqMan Universal PCR Master Mix, 0.3125 µL of primer probe mix, and 11.2 µL of nuclease-free 
water. After baseline fluorescence measurements at 25 °C, the following PCR protocol was performed: The sam-
ples were incubated for 10 min at 95°C, subjected to 40 cycles of denaturing at 92 °C for 15 s, and annealed and 
extended at 60 °C for 1 min, with a final measurement of fluorescence at 60 °C. We selected SNPs associated with 
autoimmune disease or putative functional effects15–18.
Evaluation of nivolumab efficacy and adverse events. We extracted clinical features and treatment 
histories from medical records updated until April 2018. PD-L1 expression of tumor was evaluated in pre-
treatment tumor obtained from biopsy or surgery using PD-L1 immunohistochemistry 22C3 pharmDx assay 
at a commercial clinical laboratory in SRL, Inc. (Tokyo, Japan). Nivolumab was administered intravenously to 
patients at doses of 3 mg/kg every two weeks and until evaluation of progression disease (PD) or unacceptable 
adverse events appeared. Radiographic imaging was performed every 6 to 8 weeks. The responses were evaluated 
separately by two researchers according to the Response Evaluation Criteria in Solid Tumors (RECIST) (version 
1.1). PFSs were measured from the start of nivolumab administration until the day of RECIST PD. We censored 
data from patients with no recorded clinical or radiological disease progression on the day of the last follow-up.
One of the investigators assessed the adverse events according to the Common Terminology Criteria for 
Adverse Events (version 4.0). Blood examinations were carried out every 2 weeks, and thyroid function tests 
(TSH, free T3, and free T4 (fT4) levels) were performed every 4 to 6 weeks.
Statistical analysis. We calculated the prevalences of genotypes and alleles and compared them between 
patients with adverse events and those without adverse events. We evaluated the statistical significances of the 
associations between the frequency of adverse events and genotypes using Fisher’s exact test or the Cochrane–
Armitage test, as appropriate. We calculated survival curves using the Kaplan–Meier method and used the 
log-rank test to evaluate the statistical significance of the associations between PFS and genotypes, and between 
PFS and adverse events. We performed all of the above statistical analyses using the JMP Pro statistical software 
version 12.1.0 (SAS Institute, Cary, NC, USA). We used the HaploView software (Broad Institute, Cambridge, 
MA, USA) to estimate the linkage disequilibrium, expressed as D’ and r2.
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